Dr. Heitner Enschede is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4820 Emperor Blvd
Durham, NC 27703
Education & Training
Rush University Medical CenterFellowship, Hematology and Medical Oncology, 1997 - 2000
Icahn School of Medicine at Mount SinaiClass of 1994
Publications & Presentations
PubMed
- 56 citationsVenetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.S. de Vos, Lode J. Swinnen, Ding Wang, Erin Reid, Nathan Fowler
Annals of Oncology. 2018-09-01 - 344 citationsEfficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto, Joseph R. Mikhael, Ravi Vij
Blood. 2017-11-30 - 205 citationsPromising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Asher Chanan-Khan, Andrew W. Roberts, Amit Agarwal, Thierry Facon
Blood. 2017-11-30
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
